Novartis to Acquire Anthos Therapeutics for ~$3.1B
Shots:
- Novartis to acquire Anthos (launched by Blackstone Life Sciences & Novartis in 2019) for ~$3.1B to boosts its cardiovascular portfolio with Anthos’ abelacimab; closing expected in H1’25
- As per the deal, Anthos will receive $925M upfront & is eligible to receive ~$2.15B in regulatory & commercial milestones
- Abelacimab (licensed from Novartis) showed reduced bleeding events in P-II (AZALEA) trial in comparison to SoC oral anticoagulants & is being investigated in 3 ongoing P-III (LILAC-TIMI 76 for atrial fibrillation; ASTER & MAGNOLIA for cancer-associated thrombosis) trials to prevent stroke & systemic embolism
Ref: Novartis | Image: Anthos Therapeutics
Related News:- Dawn Health & Novartis Introduce Cora BC to Support Breast Cancer Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
